Officer Files to Sell Another $1.85M in Stock, Continuing Recent Trend of Insider Sales
ANAB has more than doubled off its 52-week low of $11.402.
Summary
AnaptysBio officer Dennis Mulroy has filed a Form 144 indicating intent to sell an additional $1.85 million worth of common stock, extending a pattern of significant insider sales over the past month.
Key Events · Ownership and Investor Activity · ANAB
-
Proposed Stock Sale by Officer
Officer Dennis Mulroy has filed a Form 144 indicating intent to sell 35,000 shares of common stock, valued at approximately $1.85 million.
-
Continuation of Insider Selling Pattern
This filing extends a recent trend of significant insider sales by Mr. Mulroy, who has sold approximately $13.18 million worth of shares in the past three months.
-
Shares Acquired via Option Exercise
The shares intended for sale were acquired through a stock option exercise on the same day as the proposed sale.
Analysis · ANAB · Life Sciences
This Form 144 indicates a significant intent to sell by company officer Dennis Mulroy for approximately $1.85 million. This transaction, while acquired through option exercise, adds to a consistent pattern of insider selling from Mr. Mulroy, who has already sold over $13 million in the last three months. This ongoing distribution by a key insider could signal a desire to monetize holdings following the company's recent spin-off and share repurchase program announcement, potentially creating selling pressure on the stock.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANAB was trading at $54.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $11.40 to $72.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.